Skip to main content

The Globe and Mail

Valeant buys minority stake in Brazilian company

Valeant Pharmaceuticals International Inc. said it acquired a 19.9-per-cent stake in a Brazilian research company which is focused on tissue regeneration, for less than $10-million.

The Canadian drug maker has been increasing revenue, mostly through acquisitions, since Biovail Corp., Canada's largest publicly owned pharmaceutical company, took over U.S.-based Valeant and assumed the Valeant name in September, 2010.

Valeant said it will have representation on Sao Paulo, Brazil-based Pele Nova Biotecnologia SA's board.

Story continues below advertisement

Pele Nova produces active ingredients and skin products.

Report an error
Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.